Estimating the Economically Justifiable Price of Limited-Duration Treatment with Donanemab for Early Symptomatic Alzheimer’s Disease in the United States
Rattachement africain : us, gb. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
INTRODUCTION: The goal of this economic model is to estimate an economically justifiable price (EJP) for using donanemab for the treatment of early symptomatic Alzheimer's disease (AD) in the United States based on clinical data from the phase 3 TRAILBLAZER-ALZ 2 trial (NCT04437511). METHODS: We adapted an AD Markov state-transition model developed by the Institute for Clinical and Economic Review to estimate the EJP for donanemab at different willingness-to-pay (WTP) thresholds from the health care system perspective and the societal perspective as co-base cases. RESULTS: Assuming a WTP threshold of $150,000 per quality-adjusted life-year (QALY) gained, the model estimates a 1-year (13-dose) EJP for donanemab of $80,538 from the health care system perspective and $91,126 from the societal perspective; at a WTP threshold of $100,000 per QALY gained, the model estimates a 1-year (13-dose) EJP for donanemab of $44,691 from the health care system perspective and $55,419 from the societal perspective. Mean total treatment costs per patient at the $150,000 per QALY gained EJP derived from the health care system perspective were estimated at $77,812 based on the average number of doses of donanemab patients received in the co-base case analysis. One-way sensitivity analysis (OWSA) indicated that treatment efficacy, disease severity at the time of treatment initiation, and duration of treatment effect were the main drivers of the potential EJP. CONCLUSIONS: Results from this modeling simulation informed by the TRAILBLAZER-ALZ 2 study support an EJP for limited-duration treatment with donanemab that exceeds per-dose list prices for currently available amyloid-targeting therapies, implying potentially lower lifetime costs and better value for money.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Estimating the Economically Justifiable Price of Limited-Duration Treatment with Donanemab for Early Symptomatic Alzheimer’s Disease in the United States
- Date Crossref
- 18/09/2024
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Indiana University School of Medicine Division of Internal Medicine and Geriatrics pays non établi dans la noticeUniversité ou école supérieure
-
Indiana University – Purdue University Indianapolis pays non établi dans la noticeUniversité ou école supérieure
-
Eli Lilly (United States) pays non établi dans la noticeEntreprise
-
University of Washington Department of Pharmacy pays non établi dans la noticeUniversité ou école supérieure
-
Medical Decision Modeling (United States) pays non établi dans la noticeEntreprise
-
Eli Lilly (United Kingdom) pays non établi dans la noticeEntreprise
-
Lilly Corporate Center pays non établi dans la noticeInstitution
-
Medical Decision Modeling Inc pays non établi dans la noticeEntreprise
-
Eli Lilly and Company pays non établi dans la noticeEntreprise
Division of Internal Medicine and Geriatrics — Indiana University School of Medicine, Indiana University – Purdue University Indianapolis et Eli Lilly (United States), avec 6 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.